Agenus Inc. (NASDAQ:AGEN – Free Report) – Equities research analysts at William Blair boosted their FY2024 EPS estimates for Agenus in a research report issued to clients and investors on Monday, January 27th. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings of ($14.59) per share for the year, up from their prior estimate of ($15.34). The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. William Blair also issued estimates for Agenus’ Q4 2024 earnings at ($2.37) EPS, Q1 2025 earnings at ($1.31) EPS, Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.92) EPS, FY2026 earnings at ($2.91) EPS and FY2027 earnings at ($2.83) EPS.
Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.
Agenus Stock Down 1.9 %
NASDAQ AGEN opened at $3.54 on Thursday. The firm has a 50-day moving average price of $3.24 and a two-hundred day moving average price of $4.61. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The company has a market capitalization of $83.05 million, a P/E ratio of -0.31 and a beta of 1.27.
Institutional Investors Weigh In On Agenus
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new stake in shares of Agenus during the second quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Agenus in the 2nd quarter worth about $106,000. HighTower Advisors LLC raised its position in Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Agenus by 52.0% during the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 9,422 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Agenus by 2.1% during the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares in the last quarter. 61.46% of the stock is owned by institutional investors.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
- Five stocks we like better than Agenus
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Why Are These Companies Considered Blue Chips?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.